Latest Ratios: P/E Ratio -7.1x · EV/EBITDA N/A · ROE N/A. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $71M | $230M | $100M | $54M | $335M | $1.5B | $1.5B | $845M | $1.5B | $541M | $408M |
| Enterprise Value | $115M | $274M | $118M | $86M | $313M | $1.4B | $1.3B | $786M | $1.5B | $461M | $360M |
| P/E Ratio → | -7.09 | 7.04 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.45 | 1.90 | 0.77 | 6.34 | 5.26 | 72.58 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 2.64 | 5.28 | 3.14 | 2.91 | 4.49 | 3.04 | 1.61 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.27 | 0.92 | 10.07 | 4.93 | 68.75 | — | — | — | — | — |
| EV / EBITDA | — | 7.22 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 3.21 | 7.52 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.4% | 82.4% | 83.7% | -3.7% | -324.7% | -1286.4% | — | — | — | — | — |
| Operating Margin | 29.7% | 29.7% | -64.7% | -3219.5% | -441.2% | -1673.9% | — | — | — | — | — |
| Net Profit Margin | 27.1% | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -2014.9% | -112.4% | -91.7% | -81.4% | -92.4% | -892.9% | -553.7% | -277.9% |
| ROA | 50.5% | 50.5% | -62.2% | -101.9% | -54.1% | -64.4% | -65.9% | -79.2% | -756.9% | -496.1% | -268.5% |
| ROIC | 462.6% | 462.6% | — | -1083.7% | -137.0% | -106.7% | -91.1% | -86.8% | -94.2% | -59.9% | -24.5% |
| ROCE | 675.0% | 675.0% | — | -172.1% | -85.0% | -78.5% | -76.2% | -89.9% | -87.5% | -54.7% | -28.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.57 | 0.10 | 0.03 | 0.05 | 0.00 | — | — |
| Debt / EBITDA | 1.39 | 1.39 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.17 | -0.28 | -0.40 | -0.20 | -0.18 | -0.45 | -0.19 |
| Net Debt / EBITDA | 1.17 | 1.17 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 9.63 | 9.63 | -17.51 | -51.24 | -611.04 | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.82 | 0.82 | 0.48 | 0.72 | 3.74 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
| Quick Ratio | 0.82 | 0.82 | 0.40 | 0.65 | 3.72 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
| Cash Ratio | 0.57 | 0.57 | 0.32 | 0.36 | 3.08 | 3.51 | 6.04 | 7.05 | 7.74 | 6.01 | 26.43 |
| Asset Turnover | — | 5.97 | 1.18 | 0.05 | 0.17 | 0.04 | — | — | — | — | — |
| Inventory Turnover | — | — | 1.97 | 0.92 | 170.23 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 3.79 | 4.20 | 1452.17 | 230.93 | 17.69 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | 14.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $13M | $7M | $4M | $4M | $4M | $3M | $2M | $2M | $1M | $1M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATRA stock.
Atara Biotherapeutics, Inc.'s current P/E ratio is -7.1x. The historical average is 7.0x.
Based on historical data, Atara Biotherapeutics, Inc. is trading at a P/E of -7.1x. Compare with industry peers and growth rates for a complete picture.
Atara Biotherapeutics, Inc. has 82.4% gross margin and 29.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Atara Biotherapeutics, Inc.'s Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Imminent liquidity and solvency
Metrics are mathematically derived from official filings.
Distorted Multiples Reflecting Asset Uncertainty
As reported in recent financial statements, Atara's P/S ratio of 0.78 and EV/EBITDA of 3.66 appear artificially compressed, suggesting that the market is pricing the company as a distressed asset rather than a growth-stage biotechnology firm with a viable, long-term commercial pipeline.
The current valuation multiples are heavily skewed by the lack of recurring revenue and the exhaustion of milestone-based income. Investors should monitor these figures with caution, as they likely reflect a terminal value expectation that assumes significant dilution or a potential liquidation event rather than operational growth.
Working Capital Volatility Impairs Operations
Based on Atara's reported figures, the company's asset turnover ratio has collapsed to 0.03 in 2026Q1, indicating a severe decline in the efficiency with which the firm utilizes its remaining resource base to generate revenue compared to historical levels observed in 2025.
The extreme fluctuations in the cash conversion cycle and the inability to maintain consistent asset utilization suggest that the company's internal processes are currently optimized for survival rather than commercial scale. This inefficiency warrants further investigation into whether the firm can effectively manage its remaining inventory and receivables.
Liquidity Constraints Threaten Going Concern
According to recent SEC filings, Atara's current ratio has deteriorated to 2.16, yet this figure masks a precarious cash position of only $8.48 million, which appears insufficient to cover the company's ongoing operational burn rate without immediate and significant external capital intervention.
The quick ratio, which mirrors the current ratio due to the lack of significant inventory, highlights a total reliance on cash reserves that are rapidly depleting. This liquidity profile suggests that the company is highly vulnerable to even minor delays in clinical milestones or partnership payments.
Misapplication of Traditional Revenue Multiples
As indicated by historical financial data, the P/S ratio is the most commonly misapplied metric for Atara, as it fails to distinguish between high-margin, non-recurring milestone payments and the actual, sustainable commercial demand for the company's therapeutic products in the European or US markets.
Analysts should instead focus on the cash runway and the quality of revenue, adjusting for deferred revenue recognition to determine the true underlying commercial traction. Relying on standard revenue multiples obscures the reality that the company's income statement is currently driven by accounting events rather than operational performance.